Release issued 15th March 2004

LAKE PARK, Florida - "We are very sad to announce the death of the Chairman of our Scientific Advisory Committee and our dear friend Professor Derek Willoughby on Saturday 13th following an illness," announced Company President Kenneth Kirby.

Professor Willoughby has had a long association with the Saint Bartholomew's Hospital Medical College having joined the faculty in 1962 and was appointed Professor of Experimental Pathology in 1969. He was largely responsible for the teaching of Pathology at the College, and established the first immunology course for medical students. He designed and helped raise funds for the Pathology Museum extension at Saint Bartholomew's Hospital, and established the routine immunology diagnostic service. He served on a wide variety of College committees, culminating as a Governor of the College.

He started his career in 1947, following national service in the RAF, where he was chosen to represent Britain in the wartime Olympics that were subsequently cancelled. He was influenced through his work with many of the seminal figures of immunology including Paton, Medawar, Dale, & Fell. From his work, the origin of the macrophage, the essential role of complement in inflammation, the sequential release of mediators, characterization of many factors that are now recognised as cytokines, and more recently molecular pathways arose enabling him to see his vision of inducing the body to heal itself through resolution as opposed to suppression. With a habit of publishing in Nature, his other major strength was the development of pre-clinical models of disease and its mechanisms that are now essential in drug discovery and target validation.

Following his "retirement" he moved to Charterhouse Square and continued to run the Department of Experimental Pathology. He was responsible for inviting Sir John Vane, Nobel laureate, to the Bart's campus in 1986 and this led to the eventual establishment of the William Harvey Research Institute of which Derek was a founding Director. He continued to be active within his chosen field right up to his final illness, and the group he founded is continuing his legacy through the Centre of Biochemical Pharmacology / Experimental Pathology.

Professor Willoughby's interest in drug delivery began several years ago and he oversaw ground-breaking work in the department on the challenges of delivering liquid drug systems through the skin without the aid of a plaster or patch or other device. He identified the primary importance of minimizing drug and delivery system bonding and interactions as necessary for optimal bio-availability of the delivered drug. He foresaw the benefits of targeted tissue- specific transdermal delivery and encouraged its development. As Chairman of TransDermal's Advisory Committee, he was a tireless champion for the company's liquid technology, TDS®, making introductions to numerous potential corporate collaborators in the company's behalf.

A Fellow of Saint Johns College Cambridge, the Royal Society of Pathologists, the Institute of Biology and the Academy of Medical Sciences, he was awarded the Legion d'Honneur for his contribution towards Anglo-French Science by President Giscard d'Estang, as well as many prizes, including the first Lifetime Achievement Award by the International Association of Inflammation Societies, in Vancouver last year. These achievements were made possible with the unswerving support of his wife Pam, who survives him. He will be greatly missed by his friends and colleagues within the Institute, this company and worldwide. He will be remembered by the many students he has trained over the years many of whom now have gone on to occupy high positions in Industry and Academia.

For further details contact K.Kirby@Transdermaltechnologies.com

(30th May 2009) NSAID DANGERS COULD BE REDUCED WITH TDS (R) DELIVERY

(15th May 2009) TDS® TESTOSTERONE WILL LIKELY NOT REQUIRE BLACK BOX WARNINGS FROM FDA

(25th April 2009) TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES

(15th March 2009) TTI's LANGFORD RESEARCH PARTNERS WITH SCI

(5th January 2009) TTI'S LANGFORD RESEARCH INSTITUTE TO OCCUPY LAB SPACE